Acarix CEO Announces Trading on OTCQB Market in the US
Acarix CEO announces the company's trading on the OTCQB Market in the US, showcasing its non-invasive solution for ruling out coronary artery disease and its focus on saving healthcare costs and driving commercial success.
This news matters because it highlights Acarix's expansion into the US market, offering a non-invasive solution for ruling out coronary artery disease, potentially reducing costly and invasive procedures, and outlining the company's focus on saving healthcare costs and driving commercial success.
